Study ID: TV48125-CNS-30083 | 2019-002055-42

Study Title

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

Teva Identifier

TV48125-CNS-30083 | 2019-002055-42 Identifier


Study Status


Trial Condition(s)



Drug: Fremanezumab | Drug: Placebo

EudractCT Number


Study Description

The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM).Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of EM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of EM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to Fremanezumab.

The total duration of the study is planned to be up to 36 months.

Key Participation Requirements


Female, Male

Age Range

6 Years to 17 Years

Trial Duration

July 16, 2020 - April 11, 2022


Phase 3

Study Type


Location - Where to Participate

You may contact 1-888-483-8279 or email to obtain more information about study locations.

Contact us by location

Find out more